Tanja Raedle-Hurst

Tanja Raedle-Hurst

Auto-generated profile, based on publicly available information

Tanja Raedle-Hurst

Department of Pediatric Cardiology, Saarland University Medical Center, Homburg/Saar, Germany

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 October 2019 in PLOS ONE
Verified
Journal Article
Open access
PDF file
MAMasood Abu-Halima
Masood Abu-Halima
EMEckart Meese
Eckart Meese
MSMohamad Ali Saleh
Mohamad Ali Saleh
AKAndreas Keller
Andreas Keller
HAHashim Abdul-Khaliq
Hashim Abdul-Khaliq
TRTanja Raedle-Hurst
Tanja Raedle-Hurst
In patients with left heart failure, micro-RNAs (miRNAs) have been shown to be of diagnostic and prognostic value. The present study aims to identify those miRNAs in patients with univentricular heart (UVH) disease that may be associated with overt heart failure. A large panel of human miRNA arrays were used to determine miRNA expression profiles in the blood of 48 UVH patients and 32 healthy controls. For further selection, the most abundantly expressed miRNA arrays were related to clinical measures of heart failure and selected miRNAs validated by polymerase chain reaction were used for the prediction of overt heart failure and all-cause mortality. According to microarray analysis, 50 miRNAs were found to be significantly abundant in UVH patients of which miR-150-5p was best related to heart failure parameters. According to ROC analysis, NT-proBNP levels (AUC 0.940, 95% CI 0.873–1.000; p = 0.001), miR-150-5p (AUC 0.905, 95% CI 0.779–1.000; p = 0.001) and a higher NYHA class ≥ III (AUC 0.893, 95% CI 0.713–1.000; p = 0.002) were the 3 most significant predictors of overt heart failure. Using a combined biomarker model, AUC increased to 0.980 indicating an additive value of miR-150-5p. Moreover, in the multivariate analysis, a higher NYHA class ≥ III (p = 0.005) and miR-150-5p (p = 0.006) turned out to be independent predictors of overt heart failure. In patients with UVH, miR-150-5p is an independent predictor of overt heart failure and thus may be used in the risk assessment of these patients.

17 August 2018 in PLOS ONE
Verified
Journal Article
Open access
PDF file
MLMohammed Laqqan
Mohammed Laqqan
CSChristiane Schwaighofer
Christiane Schwaighofer
SGStefan Graeber
Stefan Graeber
TRTanja Raedle-Hurst
Tanja Raedle-Hurst
Soluble suppression of tumorogenicity 2 (sST2) has been shown to be of prognostic value in patients with chronic and acute left heart failure. The present study aims to assess the predictive value of sST2 levels in adult patients with complex congenital heart disease (CHD). In 169 consecutive patients with complex CHD and a mean age of 28.2 ± 12.0 years, sST2 levels were compared to 32 healthy controls and associated with clinical status as well as the occurrence of major adverse cardiac events (MACE). Mean follow-up time was 35.6 ± 24.9 months. In CHD patients, median sST2 levels were 29.7 ng/ml compared to 26.4 ng/ml in healthy controls (p = 0.007) and increased with different types of CHD and the severity of MACE. According to ROC analysis, the most important predictors of acute heart/Fontan failure were NYHA class III/IV (AUC 0.804, p<0.001, CI 0.668–0.941), NT-proBNP levels (AUC 0.794, p<0.001, CI 0.640–0.948), γGT levels (AUC 0.793, p<0.001, CI 0.678–0.909) and sST2 levels (AUC 0.742, p = 0.004, CI 0.626–0.858), with NYHA class III/IV as the strongest independent predictor (p<0.001). All-cause mortality was best predicted by sST2 levels (AUC 0.890, p<0.001, CI 0.741–1.000), NT-proBNP levels (AUC 0.875, p = 0.001, CI 0.766–0.984) and NYHA class III/IV (AUC 0.837, p = 0.003, CI 0.655–1.000) with sST2 as the strongest independent predictor (p<0.001). Moreover, AUC increased to 0.918 combining both biomarkers and net reclassification improved with the addition of sST2. In patients with complex CHD, sST2 may have additive value to natriuretic peptides for the prediction of all-cause mortality.

1 December 2010 in American Heart Journal
Verified
Journal Article
Closed access
TRTanja M. Raedle-Hurst
Tanja M. Raedle-Hurst
KKKarsten Koenigstein
Karsten Koenigstein
FGFrank Gruenhage
Frank Gruenhage
JRJochen Raedle
Jochen Raedle
EHEva Herrmann
Eva Herrmann
HAHashim Abdul-Khaliq
Hashim Abdul-Khaliq

8 September 2017 in PLOS ONE
Verified
Journal Article
Open access
PDF file
TRTanja Raedle-Hurst
Tanja Raedle-Hurst
MMMarieke Mueller
Marieke Mueller
AMAndreas Meinitzer
Andreas Meinitzer
WMWinfried Maerz
Winfried Maerz
TDThomas Dschietzig
Thomas Dschietzig
Homoarginine (hArg) has been shown to be of prognostic value in patients with chronic left heart failure. The present study aims to assess the clinical utility and prognostic value of hArg levels in patients with complex congenital heart disease (CHD). Plasma hArg levels were measured in 143 patients with complex CHD and compared to clinical status, echocardiographic and laboratory parameters as well as the occurrence of adverse cardiac events. Median hArg levels were 1.5 μmol/l in CHD patients as compared to 1.70 μmol/l in healthy controls (p = 0.051). Median hArg levels were lowest in patients with Fontan palliation (1.27 μmol/l) and Eisenmenger physiology (0.99 μmol/l) and decreased with the severity of adverse cardiac events with lowest values found in patients prior to death or overt heart failure (0.89 μmol/l). According to ROC analysis, the most important predictors of adverse cardiac events were hArg levels (AUC 0.837, p<0.001, CI 0.726–0.947), NYHA class (AUC 0.800, p<0.001, CI 0.672–0.928) and NT-proBNP levels (AUC 0.780, p<0.001, CI 0.669–0.891). The occurrence of overt heart failure or death due to progressive heart failure were best predicted by NYHA class (AUC 0.945, p<0.001, CI 0.898–0.992), hArg levels (AUC 0.911, p<0.001, CI 0.850–0.971) and NT-proBNP levels (AUC 0.877, p<0.001, CI 0.791–0.962), respectively. In patients with complex CHD, hArg levels can predict adverse cardiac events as reliably as or even better than NT-proBNP levels and thus might be of prognostic value in this subset of patients.

9 September 2014 in European Journal of Heart Failure
Verified
Journal Article
Open access
PDF file
RKRalf Kaiser
Ralf Kaiser
HAHashim Abdul-Khaliq
Hashim Abdul-Khaliq
HWHeinrike Wilkens
Heinrike Wilkens
EHEva Herrmann
Eva Herrmann
TRTanja M. Raedle-Hurst
Tanja M. Raedle-Hurst
Aims In patients after the Fontan procedure, assessment of a failing Fontan circuit is difficult. Natriuretic peptides failed to be reliable markers of functional status or systemic ventricular function in this patient cohort. The aim of the study was to assess the clinical utility of mid‐regional pro‐adrenomedullin (MR‐proADM) in patients after the Fontan procedure. Methods and results Plasma MR‐proADM levels were measured in 53 patients after the Fontan procedure and compared with clinical status, echocardiographic, and laboratory parameters including NT‐proBNP. Median MR‐proADM levels were 0.668 nmol/L in patients with a failing Fontan circuit as compared with 0.357 nmol/L in those without Fontan failure (P = 0.001). Levels of MR‐proADM were significantly related to the presence of Fontan failure (r = 0.444, P = 0.001), NYHA class (r = 0.434, P < 0.001), and γ‐glutamyltransferase levels (r = 0.554, P < 0.001). According to receiver operating characteristic (ROC) curve analysis, Fontan failure was best predicted by MR‐proADM [area under the curve (AUC) 0.985, P = 0.001], NT‐proBNP (AUC 0.947, P = 0.003), NYHA class (AUC 0.962, P = 0.002), and the inspiratory/expiratory ratio of the inferior vena cava diameter (AUC 0.973, P = 0.007). The optimal cut‐off of MR‐proADM for the prediction of Fontan failure was 0.520 nmol/L with a sensitivity of 100%, specificity of 93.9%, positive predictive value of 57.1%, negative predictive value of 100%, and overall accuracy of 94.3%. However, the data should also be validated in a larger cohort of patients. Conclusion Serial measurements of MR‐proADM levels may help identify patients at risk for a failing Fontan circulation especially when exceeding 0.520 nmol/L. In these patients, intensified medical care should be considered to prevent further clinical deterioration.

1 November 2013 in The Annals of Thoracic Surgery
Verified
Journal Article
Closed access
TRTanja M. Raedle-Hurst
Tanja M. Raedle-Hurst
MHMeryem Hosse
Meryem Hosse
SHSimone Hoffmann
Simone Hoffmann
HAHashim Abdul-Khaliq
Hashim Abdul-Khaliq
HSHans-Joachim Schäfers
Hans-Joachim Schäfers